



Promoting the appropriate use,
and reducing the abuse and misuse, of monitored drugs in Nova Scotia.

Important Information for Pharmacists and Prescribers

DIS Pharmacies: Default Provider for Benzodiazepine Prescriptions from out of Province Providers

For **DIS pharmacies** effective October 14, 2015, a new default provider and license number were created to streamline the submission of benzodiazepine prescriptions written by out of province providers, who are not registered with NSPMP.

This default provider **can only** be used under the following conditions:

- ✓ Prescription is for a benzodiazepine; **and**
- ✓ Prescriber is from out-of-province; **and**
- ✓ Prescriber is not registered to prescribe monitored drugs with the NSPMP and does not have an existing record in the provider registry; **and**
- ✓ Pharmacies complete the full provider profile, including the first and last name of the prescriber and provider address

Provider: **Default OOPBenzo**

License Number: **DFMDBEN99**

Can Prescriptions for Monitored Drugs be e-Prescribed?

Yes, the NSPMP Board has approved e-Prescriptions for monitored drugs via the Drug Information System. These prescriptions do not have to be written on duplicate pads.

Pharmacy staff will have to access the patient record in the DIS and retrieve the e-Prescription from the patient profile. Once it is retrieved, it can be filled. Once your pharmacy retrieves the prescription, it cannot be accessed by another pharmacy.

For the specific steps required to retrieve and fill an e-Prescription, please contact your software provider or refer to your user manual for detailed instructions.

DUR Response Messages

The Nova Scotia Prescription Monitoring Program (NSPMP) has received feedback expressing concern that pharmacies connected to the Drug Information System (DIS) are no longer receiving a DUR message when a monitored drug has been dispensed at a pharmacy not yet connected to the DIS. Due to this pharmacies are encouraged to check **eAccess** prior to dispensing a monitored drug.

Inside this Issue

DIS e-Prescribing	1
DUR Messages	1
NSPMP Compound PINs	2
Nucynta	2

Register today for
eAccess
www.nspmp.ca

PO Box 2200, Halifax NS B3J 3C6
T: 902.496.7123 or
TF: 1.877.476.7767
F: 902.481.3157
E: pmp@medavie.bluecross.ca



NSPMP Compound PINs

As of February 1, 2014, all Nova Scotia pharmacies were required to use the following PINs when submitting claims for a compound with a **MONITORED DRUG**. Please make sure to select the PIN that best corresponds with the monitored drug ingredient being used.

NSPMP Monitored Drug Chemical	OPINIONS PIN	Notes
Belladonna Tincture	99099966	
Cocaine Powder	99099974	
Codeine Powder	99099975	
Dexedrine Trial	99099976	
DHEA (prasterone)	99099977	
Diazepam Powder	99099963	Created for use by DIS pharmacies only
Fentanyl Powder	99099978	
Generic Monitored Ingredient	99099979	
Hydromorphone Powder	99099980	
Ketamine Powder	99099981	
Methadone Powder	99099993	
Methylphenidate Trial	99099984	
Midazolam Powder	99099964	Created for use by DIS pharmacies only
Morphine Powder	99099986	
Sativex Trial	99099991	
Testosterone Powder	99099965	

Nucynta®

The Nova Scotia Prescription Monitoring Program (NSPMP) has received inquiries regarding the monitored status of Nucynta®. Currently Nucynta® is not monitored by NSPMP and at this time it is not required to be written on a duplicate prescription. The monitored status of Nucynta® may change at a future date should NSPMP receive notification of a schedule change from Health Canada.